Target intelligence / Profile preview

Eukaryotic 28S ribosomal RNA sarcin–ricin loop (SRL)

Target
SRL
Molecular classification
Ribosomal RNA, RNA motif, Ribozyme component
01

Overview

The eukaryotic 28S ribosomal RNA sarcin–ricin loop (SRL) is a nearly universal and highly conserved 12-nucleotide RNA motif located in the large (60S) ribosomal subunit [PubMed: 8677602]. It serves as a critical docking site for translation elongation factors, specifically eEF-1 and eEF-2, and is essential for triggering the GTP hydrolysis required for tRNA translocation and ribosome movement along mRNA [PubMed: 31133953]. The SRL is famously the target of potent toxins known as Ribosome-Inactivating Proteins (RIPs), such as ricin from castor beans and Shiga toxins from bacteria [PubMed: 17113994]. These toxins act as N-glycosidases that specifically depurinate a single adenine residue (A4324 in humans) within the loop, while ribotoxins like alpha-sarcin cleave the phosphodiester backbone [PubMed: 20660480]. These modifications disrupt the interaction between the ribosome and elongation factors, leading to a complete and irreversible halt in protein synthesis and subsequent cell death [PubMed: 17113994]. Consequently, the SRL is a focal point in toxicology and is exploited in biotechnology to create targeted immunotoxins for cancer treatment [PubMed: 16648870].

Other names
Sarcin-ricin loopSRL28S rRNA SRLAlpha-sarcin loopSarcin/ricin domain
02

Mechanism of action

Ribosome-inactivating proteins (RIPs) target the SRL to either depurinate a specific adenine residue (N-glycosidase activity) or cleave the RNA backbone (ribonuclease activity), which irreversibly inhibits protein synthesis by preventing elongation factor binding [PubMed: 8677602, 17113994].

03

Biological functions

Translation elongationGTPase activationElongation factor bindingProtein synthesis
04

Disease associations

Toxin-mediated cell deathCancerInfectionBiodefense
05

Safety considerations

High systemic toxicityVascular leak syndromeIrreversible translation inhibitionImmunogenicity of toxin-based therapeutics
06

Interacting drugs

Ricin

5 more in the full profile.

07

Biomarkers

Depurinated 28S rRNARibosomal RNA fragmentationInhibition of protein synthesis

Beyond the preview

Go deeper on Eukaryotic 28S ribosomal RNA sarcin–ricin loop (SRL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eukaryotic 28S ribosomal RNA sarcin–ricin loop (SRL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call